Type 2 diabetes labs: what your numbers actually mean
Anchor biomarkers: HbA1c, fasting glucose, fasting insulin, triglycerides
TL;DR
- •HbA1c is the headline number, but it lags reality by 2–3 months and tells you nothing about insulin resistance — the engine driving the disease.
- •Fasting insulin + triglycerides + HDL tell you what's happening underneath the glucose numbers. These often shift years before HbA1c crosses into diabetic range.
- •Two patients with the same HbA1c can have entirely different metabolic stories. The pattern across markers — not any one number — is the diagnosis.
What each marker tells you
| Marker | Reference range | What it means |
|---|---|---|
| HbA1c | < 5.7% normal · 5.7–6.4% prediabetes · ≥ 6.5% diabetes | Average glucose over ~3 months. The diagnostic anchor. |
| Fasting glucose | < 100 mg/dL normal · 100–125 prediabetes · ≥ 126 diabetes | Snapshot of glucose after an overnight fast. Moves faster than HbA1c. |
| Fasting insulin | < 10 µIU/mL (optimal < 5) | The metabolic engine. High insulin with 'normal' glucose = insulin resistance, often years before HbA1c moves. |
| HOMA-IR | < 1.5 optimal · > 2.5 insulin resistant | Calculated from fasting glucose × fasting insulin. The single best insulin resistance index. |
| Triglycerides | < 100 mg/dL optimal · ≥ 150 elevated | Rises with insulin resistance long before glucose does. The metabolic canary. |
| HDL cholesterol | > 60 mg/dL optimal | Drops with insulin resistance. The triglyceride / HDL ratio matters more than either alone. |
| Trig / HDL ratio | < 2.0 optimal · > 3.5 strongly suggests insulin resistance | The most underused metabolic marker in primary care. |
Three real patterns Phi has seen
Example patterns · synthetic data drawn from Phi's scenario library. Not real patient records.
Pattern 1 — The "your A1C is fine" pattern.
HbA1c 5.4 (normal). Fasting glucose 92 (normal). Fasting insulin 18 (high). Triglycerides 180 (high). HDL 38 (low). Trig/HDL ratio 4.7. A primary-care reading: "Your blood sugar is fine." The full picture: this patient is several years into insulin resistance. The pancreas is working hard to keep glucose in range, and the metabolic damage is already visible in the lipid panel. Without intervention, HbA1c usually starts climbing within 1–3 years.
Example pattern · synthetic data
Pattern 2 — The "newly diagnosed prediabetic" pattern.
HbA1c 6.0 (prediabetic). Fasting glucose 108. Fasting insulin 22. Triglycerides 195. HDL 41. Trig/HDL 4.8. The patient is told "your A1C is borderline, try to lose some weight." The actual situation: full metabolic syndrome with diabetes within 5 years on the current trajectory. The Phi read: this is the highest leverage window in the entire disease — diet, sleep, walking after meals, and resistance training can reverse this in 3–6 months.
Example pattern · synthetic data
Pattern 3 — The "controlled on medication but still progressing" pattern.
HbA1c 6.8 (on metformin). Fasting glucose 124. Fasting insulin 24 (still high). Triglycerides 220. HDL 36. Trig/HDL 6.1. The chart says "diabetes, well-controlled." The body says: insulin resistance is worsening despite the medication. Metformin is masking the trajectory without addressing the underlying engine. Often a missed signal for aggressive lifestyle intervention or a second-line medication that targets insulin sensitivity directly.
Example pattern · synthetic data
Questions to bring to your doctor
- Have we ever checked my fasting insulin? What's my HOMA-IR?
- What's my triglyceride-to-HDL ratio, and what's it telling you about insulin resistance?
- Where has my HbA1c been over the last 3 years — is the trajectory flat, climbing, or improving?
- If I'm on metformin, what's the plan for actually reversing the underlying insulin resistance versus just managing glucose?
- Have we tested for diabetic complications recently — microalbumin, retinopathy screening, monofilament foot exam?
- What are realistic dietary patterns you've seen actually work for patients like me — beyond "eat better"?
- Should I be tracking continuous glucose data (e.g., a CGM trial) to see how my body responds to specific meals?
What Phi adds beyond a single number
The standard diabetes appointment focuses on the HbA1c number. Phi reads HbA1c plus the upstream metabolic engine — fasting insulin, HOMA-IR, trig/HDL ratio, inflammatory markers — and shows you the trajectory across every panel you've ever uploaded. The integrated picture tells you whether your metabolic health is genuinely improving, whether glucose control is masking worsening insulin resistance, and which specific levers (sleep, walking after meals, protein timing, resistance training) are moving your numbers based on the next panel you run.
Frequently asked questions
Can I have insulin resistance with a normal HbA1c?
Yes — and most patients do for several years before glucose numbers move. Fasting insulin elevates first, then triglycerides, then HbA1c. Catching insulin resistance early (while HbA1c is still 'normal') is the highest-leverage moment for reversal.
What's the difference between type 1 and type 2 diabetes labs?
Type 1 is autoimmune destruction of insulin-producing beta cells — fasting insulin is usually low or undetectable, and autoantibodies (GAD-65, IA-2, ZnT8) are usually positive. Type 2 is insulin resistance — fasting insulin is usually high and autoantibodies are negative.
Is HbA1c affected by anything besides blood sugar?
Yes. Anemia (especially iron deficiency), recent blood transfusions, hemoglobin variants (e.g., sickle cell trait), pregnancy, kidney disease, and high doses of vitamin C or E can all distort HbA1c. If your numbers don't match how you feel, ask whether HbA1c may be unreliable in your context.
How fast can prediabetes reverse?
Many patients see HbA1c drop 0.3–0.7% in 3 months with consistent dietary changes, daily walking, and prioritized sleep. Resistance training adds an independent insulin-sensitivity benefit. Reversing prediabetes is one of the highest-success-rate interventions in chronic disease — but it requires sustained changes, not 3-week sprints.
What's a 'normal' fasting insulin actually?
Many labs use a reference range up to 25 µIU/mL. Functional medicine and metabolic-health practitioners typically target < 10 and consider < 5 optimal. The standard reference range was set when insulin resistance was less common; it doesn't reflect what's metabolically healthy.
My A1C is great on Ozempic / Mounjaro — am I cured?
You're well-controlled. The drugs are powerful insulin sensitizers and appetite suppressants, but they don't reverse the underlying tissue insulin resistance — they manage it. If you discontinue, A1C tends to drift back toward baseline within 6–12 months unless lifestyle has shifted in parallel.
References
All citations verified against PubMed / publisher of record 2026-05-25.
- 1.American Diabetes Association Professional Practice Committee. (2024). Standards of Care in Diabetes—2024. Diabetes Care. 47(Suppl 1):S1-S321. — Current US standard for T2D diagnostic criteria and management.DOI →
- 2.Knowler WC, Barrett-Connor E, Fowler SE, et al. (Diabetes Prevention Program Research Group). (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 346(6):393-403. — Landmark DPP RCT — lifestyle reduced T2D incidence 58%, metformin 31%.PubMed →DOI →
- 3.Diabetes Prevention Program Research Group. (2009). 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study (DPPOS). Lancet. 374(9702):1677-86. — Long-term follow-up confirming durable lifestyle benefit.PubMed →DOI →
- 4.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28(7):412-9. — Original HOMA-IR derivation; basis for HOMA-IR thresholds on this page.PubMed →DOI →
- 5.Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. (2012). Prediabetes: a high-risk state for diabetes development. Lancet. 379(9833):2279-2290. — Epidemiologic synthesis on prediabetes progression rates.PubMed →DOI →
- 6.McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine. 139(10):802-9. — Basis for triglyceride-to-HDL ratio cutoff (3.0 US units).PubMed →DOI →
'Fasting insulin optimal < 5 µIU/mL' reflects functional/longevity-medicine practice positions rather than ADA guideline cutoffs. Every link above opens the PubMed abstract or publisher's DOI landing page in a new tab.
By Steve Pinedo
Co-founder, Phi Longevity
Pending clinical-team review · Last updated: 2026-05-25
Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi →